• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用校准品和质控品评估凝血酶原时间测量利伐沙班血浆浓度:一项多中心现场试验结果。

Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial.

机构信息

Hôtel-Dieu University Hospital, Paris, France.

出版信息

Clin Appl Thromb Hemost. 2012 Mar-Apr;18(2):150-8. doi: 10.1177/1076029611426282. Epub 2012 Mar 2.

DOI:10.1177/1076029611426282
PMID:22387577
Abstract

This study evaluated the prothrombin time (PT) assay for the measurement of plasma concentrations of rivaroxaban using calibrators and controls. The intra- and interlaboratory precision of the measurement was investigated in a field trial involving 21 laboratories. Each laboratory was provided with rivaroxaban calibrators and control plasma samples containing different concentrations of rivaroxaban, and PT reagents. The evaluation was carried out over 2 consecutive weeks using centrally provided and local PT reagents. A calibration curve was produced each day (for inter-run precision), and day-to-day precision was evaluated by testing 3 control plasma samples. A large interlaboratory variation (in seconds) was observed with local PT reagents. The results were less variable when expressed as rivaroxaban concentrations (ng/mL) or when central PT reagent was used (STA Neoplastine CI Plus). The widely available PT assay, in conjunction with rivaroxaban calibrators, may be useful for the measurement of peak plasma levels of rivaroxaban.

摘要

本研究评估了使用校准品和质控品的凝血酶原时间(PT)检测法来测量利伐沙班的血浆浓度。在一项涉及 21 家实验室的现场试验中,研究了该测量方法的实验室内和实验室间精密度。每个实验室都提供了利伐沙班校准品和含有不同浓度利伐沙班的质控血浆样本以及 PT 试剂。使用中央提供的和本地的 PT 试剂在连续两周内进行评估。每天生成一条校准曲线(用于评估批内精密度),并通过测试 3 个质控血浆样本来评估日间精密度。使用本地 PT 试剂时,观察到较大的实验室间变异性(以秒为单位)。当以利伐沙班浓度(ng/mL)表示或使用中央 PT 试剂(STA Neoplastine CI Plus)时,结果的变异性较小。广泛可用的 PT 检测法与利伐沙班校准品结合使用,可能有助于测量利伐沙班的血浆峰浓度。

相似文献

1
Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial.使用校准品和质控品评估凝血酶原时间测量利伐沙班血浆浓度:一项多中心现场试验结果。
Clin Appl Thromb Hemost. 2012 Mar-Apr;18(2):150-8. doi: 10.1177/1076029611426282. Epub 2012 Mar 2.
2
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.评估发色底物法检测利伐沙班血浆浓度时使用校准品和质控品的抗 Xa 因子活性。
Thromb Haemost. 2012 Feb;107(2):379-87. doi: 10.1160/TH11-06-0391. Epub 2011 Dec 21.
3
Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.评估用于检测利伐沙班(一种口服、直接的 Xa 因子抑制剂)的实验室检测方法。
Thromb Haemost. 2010 Apr;103(4):815-25. doi: 10.1160/TH09-03-0176. Epub 2010 Feb 2.
4
Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.准确测定利伐沙班水平需要不同的校准品集,但不需要添加抗凝血酶。
Thromb Haemost. 2012 Jul;108(1):191-8. doi: 10.1160/TH11-12-0832. Epub 2012 Apr 26.
5
Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban.以世界卫生组织凝血活酶为校准物,测定利伐沙班加标血浆中凝血活酶试剂的国际敏感指数。
Blood Coagul Fibrinolysis. 2011 Dec;22(8):637-41. doi: 10.1097/MBC.0b013e328349f1d6.
6
Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.利伐沙班:抗 FXa 测定法定量检测及对凝血试验的影响:瑞士 9 家实验室的研究。
Thromb Res. 2012 Apr;129(4):492-8. doi: 10.1016/j.thromres.2011.06.031. Epub 2011 Aug 15.
7
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.直接因子 Xa 抑制剂的临床实验室检测:抗 Xa 测定优于凝血酶原时间测定。
Thromb Haemost. 2010 Dec;104(6):1263-71. doi: 10.1160/TH10-05-0328. Epub 2010 Oct 26.
8
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.接受治疗剂量利伐沙班的患者凝血试验的表现。一项基于血浆峰浓度和谷浓度的横断面药效学研究。
Thromb Haemost. 2014 Jun;111(6):1133-40. doi: 10.1160/TH13-10-0871. Epub 2014 Jan 9.
9
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.实验室检测评估阿哌沙班血药浓度:三种抗 Xa 检测方法的适用性。一项多中心法国 GEHT 研究。
Thromb Haemost. 2014 Feb;111(2):240-8. doi: 10.1160/TH13-06-0470. Epub 2013 Oct 31.
10
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban.比较发色底物抗 Xa 测定和 PT 试验与 LC-MS/MS 在利伐沙班治疗患者的治疗监测中的应用。
Thromb Haemost. 2013 Oct;110(4):723-31. doi: 10.1160/TH13-04-0274. Epub 2013 Jul 11.

引用本文的文献

1
The Role of Anti-Factor Xa Activity in the Management of Ecchymosis in Patients Receiving Rivaroxaban after Total Knee Arthroplasty.抗Xa因子活性在全膝关节置换术后接受利伐沙班治疗的患者瘀斑管理中的作用
J Clin Med. 2023 Feb 1;12(3):1161. doi: 10.3390/jcm12031161.
2
Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study.新型介电微传感器监测 DOACs:一项临床研究。
Thromb Haemost. 2021 Jan;121(1):58-69. doi: 10.1055/s-0040-1715589. Epub 2020 Sep 2.
3
Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status.
确定凝血酶原时间切点以评估血浆利伐沙班过量状态。
J Thromb Thrombolysis. 2020 Feb;49(2):245-250. doi: 10.1007/s11239-019-01947-1.
4
The Development of New Factor Xa Inhibitors Based on Amide Synthesis.基于酰胺合成的新型Xa因子抑制剂的研发
Curr Drug Discov Technol. 2018;15(4):335-350. doi: 10.2174/1570163815666180215114732.
5
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.直接口服抗凝剂抗凝活性的实验室评估:一项系统评价
Chest. 2017 Jan;151(1):127-138. doi: 10.1016/j.chest.2016.08.1462. Epub 2016 Sep 13.
6
Measurement and reversal of the direct oral anticoagulants.直接口服抗凝剂的测量与逆转
Blood Rev. 2017 Jan;31(1):77-84. doi: 10.1016/j.blre.2016.08.006. Epub 2016 Sep 2.
7
Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication.非维生素K拮抗剂口服抗凝药的实验室检测:根据药物、检测方法的可及性和临床指征选择最佳检测方法
J Thromb Thrombolysis. 2016 Feb;41(2):241-7. doi: 10.1007/s11239-015-1282-7.
8
Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.通过模拟研究确定,从利伐沙班转换为华法林进行抗凝治疗时,利伐沙班对国际标准化比值的影响。
Br J Clin Pharmacol. 2015 Jun;79(6):959-66. doi: 10.1111/bcp.12571.
9
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.非维生素K口服抗凝剂抗凝活性的实验室测定
J Am Coll Cardiol. 2014 Sep 16;64(11):1128-39. doi: 10.1016/j.jacc.2014.05.065.
10
A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample.一种经过验证的高通量超高效液相色谱-串联质谱法,用于准确测定血浆样本中的利伐沙班。
J Thromb Thrombolysis. 2015 Jan;39(1):79-88. doi: 10.1007/s11239-014-1121-2.